MPM

July 24, 2017July 24, 2017

P/D Surgery Less Detrimental to MPM Patients’ Quality of Life Than EPP, Study Finds

News

Malignant pleural mesothelioma (MPM) patients who undergo pleurectomy (P/D) surgery usually live better and longer lives than those who have extrapleural pneumonectomy (EPP) surgery, finds a study featured in the Annals of Translational Medicine. ... Read more

May 19, 2017May 19, 2017

High Mesothelin Levels Linked to Poor Prognosis in Malignant Pleural Mesothelioma Patients, Study Reports

News

Soluble mesothelin, a cell surface glycoprotein predominant in several types of cancer, is an independent prognostic marker and a new potential therapeutic target for patients with malignant pleural mesothelioma (MPM), ... Read more

May 12, 2017

Study Identifies Blood Biomarkers for Diagnosing Early MPM

News

Two potential biomarkers have been identified for the diagnosis of early malignant pleural mesothelioma (MPM) in a study that compared the differences in microRNA (miRNA) expression between MPM patients and ... Read more

January 3, 2017

Gene Variations May Help Predict Survival in Mesothelioma Patients Receiving Platinum-based Chemotherapy, Study Finds

News

Variations in the immune-system-related FAS ligand (FASL) gene may help predict how long a malignant pleural mesothelioma patient who received platinum-based chemotherapy can survive without the disease progressing. A study in Egypt showed ... Read more

September 28, 2016September 28, 2016

Breath Analysis May Help Early Detection of Mesothelioma Patients, Study Finds

News

Measuring volatile organic compounds (VOCs) by breath analysis is a potent, easy-to-perform technique that can distinguish malignant pleural mesothelioma (MPM) patients from healthy people, according to a report published in the Journal of ... Read more

July 19, 2016July 19, 2016

NCCN Panel Favors New Mesothelioma Drug Combo as First-Line Therapy

News

The National Comprehensive Cancer Network (NCCN), an alliance of 27 major U.S. cancer centers, has expanded its recommendation for first-line pleural mesothelioma treatment to include the monoclonal antibody drug Avastin (bevacizumab) as a combination therapy ... Read more

January 6, 2016January 6, 2016

Novel Potential Molecular Markers Used to Predict Tumor Aggressiveness in Mesothelioma

News

Two proteins, murine double minute 2 (MDM2) and HIF1alpha, are potential molecular markers of the two most aggressive subtypes of malignant pleural mesothelioma (MPM), according to data presented in a ... Read more

December 18, 2015December 21, 2015

Malignant Pleural Mesothelioma Patients Seen to Do Best with Surgery as Therapy

News

In a new study, researchers analyzed the mesothelioma patient cases present in the large SEER database to study the effect of prognosis factors, especially the type of therapy chosen, in survival ... Read more

December 8, 2015December 8, 2015

Positive WT1 Cancer Vaccine Clinical Trial Results For Mesothelioma, Other Cancers Reported At International WT1 Conference

News

Zug, Switzerland, based SELLAS Life Sciences Group, (SELLAS), a 2012 startup clinical-stage biopharmaceutical company focused on development of novel cancer therapies, reports that positive data from the company’s clinical studies ... Read more

November 19, 2015November 19, 2015

French Study Finds Moderate Response Rate to Chemotherapy Treatment in Patients with Malignant Pleural Mesothelioma

News

A recent multicenter retrospective study conducted in France suggests that response rate to chemotherapy treatment in patients with malignant pleural mesothelioma (MPM) is low when compared to results from clinical trials. The ... Read more